---
title: "单向促癌的抗原呈递细胞"
date: 2026-01-21T00:22:20Z
draft: ["false"]
tags: [
  "fetched",
  "闲谈 Immunology"
]
categories: ["Acdemic"]
---
单向促癌的抗原呈递细胞 by 闲谈 Immunology
------
<div><section data-pm-slice="0 0 []"><span data-pm-slice="0 0 []"><span leaf=""><span textstyle="">抗原呈递癌相关成纤维细胞（apCAFs）是</span></span></span><strong><span leaf=""><span textstyle="">典型的单向促癌抗原呈递细胞</span></span></strong><span><span leaf=""><span textstyle="">，其抗原呈递功能缺乏抗肿瘤活性，反而通过免疫抑制、分泌促癌分子、重塑肿瘤微环境等机制全程支持肿瘤进展，无任何已知抗肿瘤作用。</span></span></span></section><h3><span leaf=""><span textstyle="">核心特征</span></span></h3><ul><li><section><span leaf=""><span textstyle="">本质：CAF 的特殊亚型，打破 “CAFs 仅参与基质重塑” 的传统认知，兼具成纤维细胞特性与抗原呈递功能。</span></span></section></li><li><section><span leaf=""><span textstyle="">关键分子标志：高表达 MHC II 类分子（人类 HLA-DRA、CD74；小鼠 MHC II），无 CD40、CD80、CD86 等关键共刺激分子。</span></span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100003024" data-ratio="0.6373276776246023" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/OTqlKiaoeWib4paPLGg8tLlibSY9W0xMzvVqtvKibh4Bibs7EuYA2ibH20esbOYODOATY2vPmXiaYp5OAJ1AqNjJJXBhA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="943" type="block" src="https://mmbiz.qpic.cn/mmbiz_png/OTqlKiaoeWib4paPLGg8tLlibSY9W0xMzvVqtvKibh4Bibs7EuYA2ibH20esbOYODOATY2vPmXiaYp5OAJ1AqNjJJXBhA/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf="" data-pm-slice='1 1 ["para",{"tagName":"p","attributes":{},"namespaceURI":"http://www.w3.org/1999/xhtml"}]'><span textstyle="">10.1158/1078-0432.CCR-22-1031.</span></span></p></li><li><section><span leaf=""><span textstyle="">与传统抗原呈递细胞（如树突状细胞）的区别：同时表达成纤维细胞标志物（COL1A1、COL1A2、PDGFRα），起源与空间定位依赖肿瘤微环境，功能偏向免疫调控而非单纯激活抗肿瘤免疫。</span></span></section></li></ul><h3><span leaf=""><span textstyle="">两种亚型的核心差异</span></span></h3><h3><span leaf=""><br></span></h3><table><thead><tr><th><section><span leaf=""><span textstyle="">特征</span></span></section></th><th><section><span leaf=""><span textstyle="">M-apCAF（间皮样 apCAF）</span></span></section></th><th><section><span leaf=""><span textstyle="">F-apCAF（纤维细胞样 apCAF）</span></span></section></th></tr></thead><tbody><tr><td><section><span leaf=""><span textstyle="">细胞起源</span></span></section></td><td><section><span leaf=""><span textstyle="">间皮样细胞（表达 MSLN、UPK3B、KRT19）</span></span></section></td><td><section><span leaf=""><span textstyle="">纤维细胞（造血谱系来源，表达 PTPRC/CD45、CD37）</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">特异性标志物</span></span></section></td><td><section><span leaf=""><span textstyle="">CD24、CA9、EGLN3</span></span></section></td><td><section><span leaf=""><span textstyle="">C1QC、APOC1、RARRES1</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">空间定位</span></span></section></td><td><section><span leaf=""><span textstyle="">紧邻癌细胞，集中于肿瘤核心区</span></span></section></td><td><section><span leaf=""><span textstyle="">淋巴细胞富集区，靠近免疫细胞聚集处</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">核心转录因子</span></span></section></td><td><section><span leaf=""><span textstyle="">BARX2、BHLHE41、POU5F1（调控 SPP1）</span></span></section></td><td><section><span leaf=""><span textstyle="">SPI1、RUNX3、GATA3（调控 HLA II 基因）</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">免疫功能倾向</span></span></section></td><td><section><span leaf=""><span textstyle="">诱导免疫抑制性 T 细胞（表达 TIGIT、CTLA4）</span></span></section></td><td><section><span leaf=""><span textstyle="">参与淋巴细胞招募（分泌 CCL5），兼具免疫激活与抑制（分泌 SPP1）</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">富集癌症类型</span></span></section></td><td><section><span leaf=""><span textstyle="">肾透明细胞癌、肝癌、结直肠癌、卵巢癌</span></span></section></td><td><section><span leaf=""><span textstyle="">腹膜转移癌、肾透明细胞癌、皮肤鳞癌、胃癌</span></span></section></td></tr></tbody></table><hr><h3><span leaf=""><span textstyle="">核心功能与作用机制</span></span></h3><ol><li><strong><span leaf=""><span textstyle="">抗原呈递功能</span></span></strong><section><span leaf=""><span textstyle="">通过 MHC II/HLA II 分子呈递肿瘤抗原，但因缺乏共刺激分子，无法有效激活 T 细胞，反而可能诱导调节性 T 细胞（Treg）扩增，抑制抗肿瘤免疫。</span></span></section></li><li><strong><span leaf=""><span textstyle="">调控肿瘤微环境</span></span></strong></li></ol><ul><li><section><span leaf=""><span textstyle="">分泌 SPP1（核心介质）：促进癌细胞迁移、侵袭、集落形成，诱导肌成纤维细胞（myCAF）分化，形成纤维化屏障。</span></span></section></li><li><section><span leaf=""><span textstyle="">介导细胞间互作：M-apCAF 通过 SPP1 与癌细胞、免疫细胞结合；F-apCAF 通过配体 - 受体信号（如 CCL5-CD44）招募淋巴细胞。</span></span></section></li></ul><li><strong><span leaf=""><span textstyle="">促进治疗抵抗</span></span></strong><section><span leaf=""><span textstyle="">在胰腺癌（PDAC）中，M-apCAF 富集于 SPP1 + 肿瘤区域，增强癌细胞对化疗（如 FOLFIRINOX）的抵抗性；SPP1 中和抗体可逆转该表型。</span></span></section></li><h3><span leaf=""><span textstyle="">临床意义</span></span></h3><ul><li><section><span leaf=""><span textstyle="">预后标志物：M-apCAF（CD24、CA9、EGLN3）与 F-apCAF（C1QC、APOC1、RARRES1）的特征基因高表达，均与癌症患者不良预后显著相关。</span></span></section></li><li><section><span leaf=""><span textstyle="">治疗靶点：SPP1 是 apCAFs 介导肿瘤恶化的核心分子，已有 SPP1 人源化抗体进入临床研究，可作为腹膜转移癌、胰腺癌等的潜在治疗靶点。</span></span></section></li><li><section><span leaf=""><span textstyle="">患者分层：iCMS3 亚型腹膜转移癌中 F-apCAF 富集，免疫活性更高，可作为免疫治疗响应的潜在预测指标。</span></span></section></li></ul><h3 data-pm-slice="0 0 []"><span leaf=""><span textstyle="">与传统抗原呈递细胞（树突状细胞、巨噬细胞）对比</span></span></h3><h3 data-pm-slice="0 0 []"><span leaf=""><br></span></h3><table><thead><tr><th><section><span leaf=""><span textstyle="">对比维度</span></span></section></th><th><section><span leaf=""><span textstyle="">抗原呈递癌相关成纤维细胞（apCAFs）</span></span></section></th><th><section><span leaf=""><span textstyle="">树突状细胞（DC）</span></span></section></th><th><section><span leaf=""><span textstyle="">巨噬细胞（Macrophage）</span></span></section></th></tr></thead><tbody><tr><td><section><span leaf=""><span textstyle="">细胞起源</span></span></section></td><td><section><span leaf=""><span textstyle="">双起源：M-apCAF（间皮样细胞）、F-apCAF（纤维细胞，造血谱系来源）</span></span></section></td><td><section><span leaf=""><span textstyle="">造血干细胞（骨髓来源）</span></span></section></td><td><section><span leaf=""><span textstyle="">造血干细胞（骨髓来源，外周血单核细胞分化）</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">核心标志物</span></span></section></td><td><section><span leaf=""><span textstyle="">共性：HLA II（CD74、HLA-DRA）、成纤维细胞标志物（COL1A1、COL1A2、PDGFRα）；亚型特异：M-apCAF（CD24、MSLN）、F-apCAF（CD45/PTPRC、C1QC）</span></span></section></td><td><section><span leaf=""><span textstyle="">CD11c、MHC II、CD83、CD1a（未成熟）、CD80/CD86（成熟）</span></span></section></td><td><section><span leaf=""><span textstyle="">CD68、CD14、MHC II、CD163（M2 型）、iNOS（M1 型）</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">抗原呈递核心分子</span></span></section></td><td><section><span leaf=""><span textstyle="">高表达 HLA II 类分子（人类 HLA-DRA/CD74；小鼠 MHC II）</span></span></section></td><td><section><span leaf=""><span textstyle="">高表达 MHC I/II 类分子，抗原加工呈递能力最强</span></span></section></td><td><section><span leaf=""><span textstyle="">表达 MHC I/II 类分子，抗原加工呈递效率中等</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">共刺激分子表达</span></span></section></td><td><section><span leaf=""><span textstyle="">缺乏关键共刺激分子（CD40、CD80、CD86）</span></span></section></td><td><section><span leaf=""><span textstyle="">成熟 DC 高表达 CD40、CD80、CD86、CD40L</span></span></section></td><td><section><span leaf=""><span textstyle="">中等表达 CD40、CD80，M2 型低表达共刺激分子</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">主要免疫功能</span></span></section></td><td><section><span leaf=""><span textstyle="">呈递抗原但无法激活 T 细胞，诱导免疫抑制（调节性 T 细胞扩增）；参与淋巴细胞招募（F-apCAF 分泌 CCL5）</span></span></section></td><td><section><span leaf=""><span textstyle="">激活初始 T 细胞，启动适应性免疫；分泌细胞因子调控免疫应答方向</span></span></section></td><td><section><span leaf=""><span textstyle="">吞噬清除病原体 / 肿瘤细胞；呈递抗原；M1 型促炎症、抗肿瘤，M2 型免疫抑制、促修复</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">肿瘤微环境中的作用</span></span></section></td><td><section><span leaf=""><span textstyle="">促进肿瘤形成、腹膜转移、纤维化屏障形成、化疗 / 免疫治疗抵抗</span></span></section></td><td><section><span leaf=""><span textstyle="">成熟 DC 促进抗肿瘤免疫；未成熟 / 耐受型 DC 诱导免疫耐受，促进肿瘤进展</span></span></section></td><td><section><span leaf=""><span textstyle="">M1 型：杀伤肿瘤细胞、抑制血管生成；M2 型：促进肿瘤增殖、转移、血管生成、免疫抑制</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">关键分泌分子</span></span></section></td><td><section><span leaf=""><span textstyle="">核心：SPP1（ osteopontin）；其他：CCL5（F-apCAF）、LAIR1（免疫抑制）</span></span></section></td><td><section><span leaf=""><span textstyle="">IL-12、IL-6、TNFα、趋化因子（CCL19、CCL21）</span></span></section></td><td><section><span leaf=""><span textstyle="">M1 型：TNFα、IL-6、IL-1β、iNOS；M2 型：IL-10、TGFβ、VEGF、Arg1</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">与肿瘤的核心关系</span></span></section></td><td><section><span leaf=""><span textstyle="">促瘤（无抗肿瘤功能，全程支持肿瘤进展）</span></span></section></td><td><section><span leaf=""><span textstyle="">双向：成熟 DC 抗肿瘤，耐受型 DC 促瘤</span></span></section></td><td><section><span leaf=""><span textstyle="">双向：M1 型抗肿瘤，M2 型促瘤</span></span></section></td></tr><tr><td><section><span leaf=""><span textstyle="">空间分布特征</span></span></section></td><td><section><span leaf=""><span textstyle="">肿瘤局部特异：M-apCAF 紧邻癌细胞，F-apCAF 富集于淋巴细胞区域</span></span></section></td><td><section><span leaf=""><span textstyle="">淋巴结、肿瘤浸润区（成熟 DC）；外周组织（未成熟 DC）</span></span></section></td><td><section><span leaf=""><span textstyle="">广泛分布于肿瘤间质、肿瘤核心区（M2 型为主）、炎症浸润区（M1 型为主）</span></span></section></td></tr></tbody></table><h3><span leaf=""><br></span></h3><section><span leaf=""><span textstyle="">参考资料</span></span></section><p><span leaf=""><span textstyle="">Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity，Clin Cancer Res. 2023 Mar 14;29(6):1009-1016. doi: 10.1158/1078-0432.CCR-22-1031.</span></span></p><p><span leaf=""><span textstyle="">Chen et al.Single-cell resolution spatial analysis of antigenpresenting cancer-associated fibroblast niches，Cancer Cell 43, 2224–2240</span></span></p><p><span leaf=""><span textstyle="">Badran,O.;Cohen,I.; Bar-Sela, G. Cancer-Associated Fibroblasts in Solid Tumors and Sarcomas: Heterogeneity, Function, andTherapeuticImplications. Cells 2025, 14, 1398. https://doi.org/ 10.3390/cells14171398</span></span></p><section nodeleaf=""><mp-common-profile data-pluginname="mpprofile" data-nickname="闲谈 Immunology" data-alias="xiantanimmunology" data-from="0" data-headimg="http://mmbiz.qpic.cn/mmbiz_png/PSAKibajvwRY6ibhAvU9rdNiaEpUcd81BfRIs9SDSpC2mxkv8CcrI1F3TAMZhyj7AsnsPpCFfz599XUdudV23nILA/0?wx_fmt=png" data-signature="专注ImmunoBiology，桥接基础研究与产业应用！" data-id="MzYzMzUzNjcyNw==" data-is_biz_ban="0" data-service_type="1" data-verify_status="2"></mp-common-profile></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/FeE6fRZH7t46VDv4OoMlsQ",target="_blank" rel="noopener noreferrer">原文链接</a>
